Journal of Clinical Oncology
Articles in this Issue
Clinical efficacy of enfortumab vedotin-pembrolizumab (EV-P) in locally advanced (LA) or metastatic urothelial carcinoma (mUC): A real-world retrospective study.
745 Background: The combination of EV-P therapy has recently been approved as first-line (1L) therapy for patients with LA/mUC based on the results of the...
Circulating tumor DNA as a prognostic biomarker to predict retroperitoneal histology in patients undergoing retroperitoneal lymph node dissection.
646 Background: Serum tumor markers (STM) are used in the management of patients with testicular cancer. However, a proportion have normal STM even with c...
Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
216 Background: In this prospective study at a community-based hospital, we conducted comprehensive genomic testing to identify pts with actionable varian...
Optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions.
581 Background: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) represents a promising approach for advanced solid tumor treatment...
Prognostic significance of tumor immune microenvironment dynamics in prostate cancer induced by androgen deprivation therapy.
398 Background: The dynamics of the prostate cancer microenvironment through androgen regulation are unclear. In this study, we analyzed the relationship...
Clinicopathological characteristics of cancer of unknown primary (CUP) with renal profile using gene expression profiling (GEP) based cancer classification.
456 Background: CUP is a rare and heterogenous clinicopathologic syndrome with unidentifiable origin at time of diagnosis. Based on immunophenotyping, spe...
An open-label phase 1, window-of-opportunity study of ultrasound-guided long acting periprostatic neuraxial block with ethanol in patients with high-risk prostate cancer.
391 Background: Patients (pts) with high-risk prostate cancer (PCa) have an elevated risk of disease recurrence/progression after definitive therapy. Thes...
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
LBA18 Background: The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs...
Evaluating the impact of a community-based prostate cancer screening program.
324 Background: One out of eight men in the U.S. will be diagnosed with prostate cancer during his lifetime. Early detection, often by routine screening,...
Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.
729 Background: Adjuvant platinum-based chemotherapy after radical nephroureterectomy (RNU) was a strong recommendation for patients with pT2–4 and/or pN+...
Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma.
762 Background: Abnormalities in body composition, including sarcopenia and myosteatosis, have been identified as prognostic factors in patients (pts) rec...
Assessing molecular heterogeneity of prostate cancer biopsy sampling: Insights from the MAST trial.
240 Background: Prostate cancer is heterogeneous and multi-focal, and biopsy sampling often undersamples the tumor or samples different tumor foci. Such h...
Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study.
534 Background: Pts with VHL disease are at risk of developing malignant tumors such as renal cell carcinoma (RCC) due to VHL gene...
Sensitive tissue-based detection of AR-V7 and other androgen receptor alterations using combined DNA/RNA comprehensive genomic profiling.
195 Background: Mechanisms of resistance to agents targeting the androgen receptor (AR) axis in prostate cancer (PC) include AR am...
Clinical significance of urotensin 2 plasma level in patients diagnosed with prostate cancer.
249 Background: Urotensin-II is a small somatostatin-like cyclic peptide characterized by its potent vasoconstrictor activity. Urotensin-II (UT-II) and it...
Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer.
690 Background: VI-RADS is widely used to identify muscle-invasive bladder cancer (MIBC). However, it is not known whether structural category (SC; VI-RAD...
The CABOLD study: A real life prospective cohort evaluating the combination of cabozantinib and nivolumab among older patients with renal-cell carcinoma.
TPS607 Background: In the era of combination therapy, and due to age-related physiological changes, management of older patients with Clear-cell renal cel...
Metastasis-directed treatment (MDT) for patients (pts) with non-clear cell renal cell carcinoma (nccRCC): Results from a matched 15-year retrospective cohort.
497 Background: nccRCC represents a diverse group of diseases with variable clinicopathological features. We aimed to evaluate the impact of MDT on clinic...
Assessment of <i>PARP1</i> mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer.
202 Background: While several PARP inhibitors are approved in combination with hormonal therapies for metastatic castrate resistant prostate cancer (CRPC)...
Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).
793 Background: Interim results of the randomized phase II trial of neoadjuvant tislelizumab +/- oral APL-1202 (nitroxoline) revealed promising pathologic...
Outcomes of high-risk prostate-specific antigen level during active surveillance with targeted and systematic prostate biopsy.
343 Background: National Comprehensive Cancer Network (NCCN) recommendations for very low to intermediate-risk prostate cancer (PCa) include active survei...
Determining optimal patient selection for high-intensity focused ultrasound (HIFU) for prostate cancer: Results from a single-institution cohort.
362 Background: High-intensity focused ultrasound (HIFU) uses magnetic resonance imaging (MRI) and transrectal ultrasound to target areas affected by pros...
Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study.
825 Background: Pembrolizumab (Pb) is a treatment (trt) for advanced urothelial carcinoma (aUC). In this study, we analyzed the fecal metaproteome of aUC...
Pathogenic germline variant prevalence and genetic testing outcomes in patients with urothelial carcinoma.
741 Background: Urothelial carcinoma (UC) is rarely attributed to hereditary causes, but recent studies suggest inherited factors may play a larger role....
Late onset of apalutamide-related skin toxicity in Black men with advanced prostate cancer: A diverse real-world analysis.
23 Background: Apalutamide (APA)- related skin toxicity is a common adverse reaction of varying incidence by ethnicity 1 . We have...